New Stock Preview | Maiketian submits another application: the two faces behind turning losses into profits- high hanging goodwill and dependency on Veekoheeng

In the lineup in front of the Hong Kong Stock Exchange, Shenzhen Micotian Biomedical Technology Co., Ltd. (hereinafter referred to as "Micotian") is a familiar face. On March 11, this medical device enterprise led by the "Mindray team" and with over 20% shareholding by Hillhouse Capital, immediately submitted a new application on the same day that the initial prospectus was invalidated. This comeback not only updated key financial data showing a shift from loss to profit for the full year of 2025, but also saw its latest valuation rise to 8.245 billion RMB. However, behind this story of rapid growth through acquisitions, high goodwill, turmoil in distributor channels, and regulatory "flaws" are multiple hidden concerns awaiting the scrutiny of the market. The "financial dualism" behind the shift from loss to profit The prospectus shows that continuous capital injection has become the "ammunition depot" for Micotian's acquisition and expansion. Since 2017, the company has rapidly built up three core business sectors - life support, minimally invasive intervention, and in vitro diagnostics - through a series of acquisitions. By the end of 2025, the company had commercialized 330 products, including 60 life support products, 110 minimally invasive intervention products, and 160 in vitro diagnostic products, covering over 140 countries and regions globally, with overseas revenue accounting for 48%; domestically, products were distributed to over 6,000 hospitals, of which about 90% were tertiary grade A hospitals, while over 40 pipeline candidate products were still in progress. After the completion of share subscription in 2023, Micotian's post-investment valuation rose to 8.245 billion RMB, an increase of approximately 24.77 times from the 320 million RMB raised during the A-round financing in 2016. This demonstrates the market's recognition of its acquisition integration logic. It is worth noting that Micotian also completed two rounds of share transfers in 2023 and 2024. The share transfer in 2023 received an investment amount of 161 million RMB, while the share transfer in 2024 received 89.96 million RMB. Since both rounds were stock transfers, it indirectly reflects that the company's valuation has been maintained at over 8 billion RMB, with no significant fluctuations. According to observations, the successful shift from loss to profit in 2025 provided key support for Micotian's second push for listing on the Hong Kong Stock Exchange. However, a deeper analysis of its financial structure reveals a distinct "duality" - substantial improvement in profitability and the accumulation of risks from post-acquisition aftermath. On one hand, the improvement in operational efficiency is driving the turning point in profitability. From the perspective of revenue quality, from 2023 to 2025, the company's revenue increased from 1.313 billion RMB to 1.619 billion RMB, with a year-on-year growth rate of 15.71% in 2025, an increase of 5.6 percentage points from the previous year. More importantly, the continuous optimization of gross margin - from 49.6% to 53.7% during the same period, with an accumulated increase of 4.1 percentage points. This increase far exceeds the range that can be explained by purely expanding revenue, indicating a shift towards higher value-added products (such as an increase in the proportion of minimally invasive intervention consumables) and the cost benefits from supply chain integration. The breakthrough in profitability is a significant milestone. After a net loss of 387 million RMB accumulated from 2022 to 2024, the company achieved a net profit of 50.738 million RMB in 2025, with an adjusted net profit (excluding non-cash items such as stock payments and amortization of intangible assets) reaching 129 million RMB, corresponding to a net profit margin of 3.13%. This means that the company has crossed the threshold of "strategic losses," and operational cash flow is expected to also turn positive - a key signal for a medical device platform company transitioning from an investment period to a harvesting period. On the other hand, there is a profit "reservoir lake" under high goodwill. The growth model driven by acquisitions is pushing the company towards another risk exposure. By the end of 2025, the goodwill recorded due to acquisitions of companies such as Penlon in the UK, Jiangsu Weidekang Medical, and Vedefar reached a high level of 928 million RMB, accounting for 49.47% of the net assets as of the same period (18.76 billion RMB). Among them, only Weidekang Medical contributed to goodwill of 914 million RMB, accounting for 98.5% of the total goodwill, creating a highly concentrated risk of impairment. Although the company has adopted a strategy of "progressive integration" to manage the acquired entities, and both Penlon and Weidekang Medical have seen a steady growth in gross profit in recent years, warning signs are emerging: firstly, Penlon's operations have slowed down, with a 16.41% year-on-year decline in revenue in 2025, already below the level in 2023, indicating that its synergies in the anesthesia and respiratory pathway field have not fully realized. Secondly, the dependence on Weidekang is increasing. The minimally invasive intervention business led by Weidekang has become the company's largest source of revenue, accounting for 50% of revenue in 2025. This means that over half of the company's income relies on a single acquired target, and if its future growth slows down, core product prices drop, or market competition intensifies, it will have a "double kill effect" on the financial statements - impacting revenue and triggering goodwill impairments, directly eroding current profits. Success and hidden concerns The prospectus shows that Micotian's business structure has undergone strategic reshaping over the past three years. The company has shifted from a balanced layout of "life support, minimally invasive intervention, and in vitro diagnostics" to a growth model driven solely by minimally invasive intervention. In 2023, the life support and minimally invasive intervention sectors were of similar scale (564 million vs. 587 million), forming the foundation of the company. However, by 2025, this situation had completely changed: minimally invasive intervention became the absolute pillar. The revenue from this sector jumped from 587 million to 812 million, with a two-year compound growth rate of 17.7%. The revenue proportion increased from 44.7% to 50.1%, dominating the company's operations. The life support sector experienced severe fluctuations, with revenue in 2024 shrinking to 494 million (a 12.4% year-on-year decline). In 2025, it rebounded to 613 million but has not yet shown a stable growth trajectory. As a traditional cash cow business, the revenue of the diagnostic sector increased from 163 million to 194 million, with a two-year compound growth rate of only 9.2%, much lower than the industry average, showing signs of falling behind. In conclusion, Micotian is no longer a platform company with balanced "life support + minimally invasive intervention + in vitro diagnostics" sectors, but a specialty medical device company heavily dependent on minimally invasive interventions. The effects of the Weidekang acquisition are increasingly evident, but it also means that the company's fate is deeply tied to the prosperity of the digestive endoscopy field. The upcoming challenge is whether this singular focus can drive other sectors out of the muddy waters and truly achieve comprehensive profitability. From a shift of focus from "three horses" to "single-core driving," Micotian's growth path clearly reflects a typical paradigm of Chinese medical device companies achieving breakthrough development through acquisitions. The effect of Weidekang's inclusion not only supports the foundation of a multi-billion valuation but also propels the company towards a turning point in profitability - the shift from loss to profit in 2025 marks the crossing of the "investment period" bloodline, entering a critical phase of "realization." However, the other side of the coin cannot be overlooked: with 928 million RMB in goodwill hanging high, over half of the income tied to a single acquisition target, and weak growth in the life support and in vitro diagnostics sectors. When the "Weidekang dependence syndrome" becomes a core variable in the company's fundamentals, any policy fluctuations or intensified competition in the sector could trigger significant fluctuations in the profit statement.